Skip to main content
. 2019 Dec 9;12(Suppl 1):21–29. doi: 10.1007/s13193-019-01014-4

Fig. 1.

Fig. 1

Performance of CAB. a Survival (KM) curve using CAB-based risk categorization on a retrospective mixed cohort of chemotherapy-treated and chemotherapy-naïve (endocrine therapy alone treated) patients. b Survival analysis using CAB-based categorization with chemotherapy-naïve patient cohort